Home > What we do > Medicine & Healthcare > hMedicine > hMedicine Story

Hadasit and Oramed Pharmaceuticals Collaborate for Development of Oral Delivery System Technology

Hadasit, the Hadassah University Medical Center's technology transfer company, has signed a contract with Oramed Pharmaceuticals to continue working together on the development of Oramed's platform technology for the oral delivery of medicine, such as insulin. Oramed, a publicly traded company, is the outgrowth of 30 years of research conducted at Hadassah, mainly by the late Prof. Chanoch Bar-On in the Diabetes Unit.

Oramed's flagship product is an oral insulin capsule, which is currently in Phase 2 clinical trials. The oral insulin capsule has the potential to change the current paradigm of treatment for the 285 million people suffering with diabetes worldwide.

Date: 11/14/2011


More hMedicine Stories




Hadasit, Hadassah’s Technology Transfer Arm, Reviews 2012’s Accomplishments

When the Hadassah University Medical Center’s physicians suggest a solution to a medical problem which can lead to the development of a new medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its feasibility and supports the promotion of those viable ideas with innovation potential. Although 2012 has been “a year full of challenges for the life science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer, Hadasit still signed 125 agreements for clinical trials, all to be done at Hadassah. In addition, Hadasit signed 15 agreements for cooperation and commercialization of technologies that were developed at Hadassah. Click here to read the latest Newsletter from Hadasit >>

   |  Who We Are  |  What We Do  |  Where We Do It  |  Read About It  |  Join Now  |  Donate  |
  |  Login  |  Contact Us  |  Careers  |  Terms & Conditions  |  
Copyright ©2014 Hadassah is a registered trademark of Hadassah, the Women's Zionist Organization of America